相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Charlson Comorbidity Index: A Critical Review of Clinimetric Properties
Mary E. Charlson et al.
PSYCHOTHERAPY AND PSYCHOSOMATICS (2022)
The multiple sclerosis prodrome: Emerging evidence, challenges, and opportunities
Helen Tremlett et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting
Huah Shin Ng et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2021)
Apparent changes in the epidemiology and severity of multiple sclerosis
Nils Koch-Henriksen et al.
NATURE REVIEWS NEUROLOGY (2021)
Medication adherence in multiple sclerosis as a potential model for other chronic diseases: a population-based cohort study
Charity Evans et al.
BMJ OPEN (2021)
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
Anna He et al.
LANCET NEUROLOGY (2020)
The COVID-19 pandemic and the use of MS disease-modifying therapies
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Multiple sclerosis: effect of beta interferon treatment on survival
Elaine Kingwell et al.
BRAIN (2019)
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
Tomas Kalincik et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Establishing the Incidence and Prevalence of Multiple Sclerosis in Saskatchewan
Lina H. Al-Sakran et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2018)
A case for gender-based approach to multiple sclerosis therapeutics
Maria K. Houtchens et al.
FRONTIERS IN NEUROENDOCRINOLOGY (2018)
The long-term impact of early treatment of multiple sclerosis on the risk of disability pension
Erik Landfeldt et al.
JOURNAL OF NEUROLOGY (2018)
Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?
Joao J. Cerqueira et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
Lower prevalence of multiple sclerosis in First Nations Canadians
Ruth Ann Marrie et al.
NEUROLOGY-CLINICAL PRACTICE (2018)
Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making
Vaibhav B. Katkade et al.
JOURNAL OF MULTIDISCIPLINARY HEALTHCARE (2018)
Importance of early treatment initiation in the clinical course of multiple sclerosis
Andrius Kavaliunas et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Importance of early treatment initiation in the clinical course of multiple sclerosis
Andrius Kavaliunas et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study
Hanne Marie Boe Lunde et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2017)
Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments
Ann Marie Weideman et al.
FRONTIERS IN NEUROLOGY (2017)
Adherence and persistence to drug therapies for multiple sclerosis: A population-based study
Charity Evans et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Brain health: time matters in multiple sclerosis
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010)
Elaine Kingwell et al.
JOURNAL OF NEUROLOGY (2015)
Influence of treatments in multiple sclerosis disability: A cohort study
Eleonora Cocco et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study
Emmanuelle Leray et al.
PLOS ONE (2015)
The Incidence and Prevalence of Multiple Sclerosis in Nova Scotia, Canada
Ruth Ann Marrie et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2013)
Impact of Disease-Modifying Therapies on the Survival of Patients with Multiple Sclerosis in Taiwan, 1997-2008
Ching-Piao Tsai et al.
CLINICAL DRUG INVESTIGATION (2013)
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
Ludwig Kappos et al.
JOURNAL OF NEUROLOGY (2013)
Mortality in patients with multiple sclerosis
Antonio Scalfari et al.
NEUROLOGY (2013)
Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada
E. Kingwell et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
The AAN response to evidence-based medicine: promise and pitfalls
Gary S. Gronseth et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Survival in MS A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial
D. S. Goodin et al.
NEUROLOGY (2012)
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study
Douglas S. Goodin et al.
BMJ OPEN (2012)
New perspectives in the natural history of multiple sclerosis
Helen Tremlett et al.
NEUROLOGY (2010)
The rising prevalence and changing age distribution of multiple sclerosis in Manitoba
R. A. Marrie et al.
NEUROLOGY (2010)
Immortal time bias in pharmacoepidemiology
Samy Suissa
AMERICAN JOURNAL OF EPIDEMIOLOGY (2008)
Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial
M. Rovaris et al.
MULTIPLE SCLEROSIS (2007)
Methods for evaluation of medication adherence and persistence using automated databases
Susan E. Andrade et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2006)
分享论文
